[ Price : $8.95]
FDA has issued a reminder to more than 2,200 clinical trial sponsors and researchers, urging them to comply with federal requireme...[ Price : $8.95]
A panel of industry leaders, policy experts, and FDA say broader adoption of external control arms in oncology drug development wi...[ Price : $8.95]
FDA cites an Indian drug manufacturer for deficiencies in laboratory testing and quality control procedures following an inspectio...[ Price : $8.95]
FDA is reportedly considering ophthalmologist and biotech executive Houman Hemmati as CBERs next director.[ Price : $8.95]
FDA accepts for priority review a Daiichi Sankyo and Merck BLA for ifinatamab deruxtecan, an investigational therapy for patients ...[ Price : $8.95]
FDA cites Pfizer over social media promotions for its cancer drug Adcetris, stating that certain Facebook advertisements are false...[ Price : $8.95]
A new policy analysis from the Cato Institute urges FDA to modernize its regulatory framework for artificial intelligence in healt...[ Price : $8.95]
FDA issues Replimune another complete response letter, declining to approve its BLA for vusolimogene oderparepvec in combination w...